Skip to main content
From Bio Co., Ltd. logo

From Bio Co., Ltd. — Investor Relations & Filings

Ticker · 377220 ISIN · KR7377220009 KO Manufacturing
Open in API
Filings indexed 112 across all filing types
Latest filing 2023-02-22 Earnings Release
Country KR South Korea
Listing KO 377220

About From Bio Co., Ltd.

https://frombio-company.co.kr/default/e…

From Bio Co., Ltd. is a healthcare company specializing in the research, development, manufacturing, and sale of health functional foods and dietary supplements. The company operates across the entire value chain, from sourcing new raw materials to production in its GMP-certified facility. A significant focus is placed on research and development through its specialized Food, Bio, and New Drug laboratories. These divisions work on discovering and verifying novel functional ingredients for health foods while also developing new pharmaceuticals, including treatments for alopecia and first-in-class drugs. The product portfolio addresses specific health needs such as joint health (Boswellia), stomach comfort (Mastic Gum), eye health (Bilberry), and body fat reduction (Wild Mango), emphasizing the use of natural, plant-based ingredients.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (FromBio) announcing a significant change (over 30%) in revenue or profit structure. This is a standard regulatory disclosure requirement in the Korean market (DART system) for material financial changes. Since it provides specific financial highlights and reasons for the variance rather than just announcing the availability of a report, it is classified as an Earnings Release (ER) equivalent in the context of regulatory disclosures. FY 2022
2023-02-22 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (the 17th Annual General Meeting). It does not contain the full report or proxy materials themselves, but rather serves as a formal notice of the record date for shareholder rights. Given its nature as a regulatory notification of a corporate event, it fits best under the RNS category.
2022-12-15 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Frombio Co., Ltd.' covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial data, business operations, management discussions, and production information. As it is a comprehensive financial report for a period shorter than a full fiscal year (Q3), it falls under the 'Interim / Quarterly Report' category. 9M 2022
2022-11-14 Korean
[기재정정]분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '주식회사 프롬바이오' covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial data, business descriptions, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by CJ Investment and its related funds in the company FromBio. This type of filing is used to notify the market and regulators of significant changes in shareholding levels, which falls under the 'Major Shareholding Notification' category.
2022-10-12 Korean
[기재정정]신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the company 'FromBio' regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자등). It details changes to the investment amount for a new office building construction due to rising raw material costs and design changes. Since this is a specific regulatory disclosure regarding capital expenditure and facility investment that does not fit into the other specialized categories like M&A or Share Issues, it falls under the 'Regulatory Filings' category.
2022-08-19 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.